IP Library Granted Patent US 8,956,659
Granted Patent B2
US 8,956,659 · App. 14/056,049 · Granted Feb 17, 2015

Fulvestrant nanosphere/microsphere and preparative method and use thereof

Inventors: Renle Hu (Xi'an, CN); Jiucheng Wang (Xi'an, CN); Yaqi Jiao (Xi'an, CN); Hua Liang (Xi'an, CN); Duohao Ding (Xi'an, CN)
Assignee: Xi'an Libang Pharmaceutical Technology Co., Ltd.
A61K47/34A61K9/0019A61K9/0024A61K9/1641A61K9/1647A61K9/5031A61K9/5089A61K31/565A61K9/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,956,659
App. No.
14/056,049
Granted
Feb 17, 2015
Kind
B2
Abstract

Fulvestrant nanosphere/microsphere and preparation method and use thereof are provided in the present invention. The carrier material of the fulvestrant nanosphere/microsphere is methoxy ended polyethylene glycol-polylactic acid block copolymer. The nanosphere/microsphere is prepared by solvent-nonsolvent method, in-liquid drying method and/or spray drying method, and has the features of high drug loading and high encapsulation efficiency, controllable release of medicine and no irritant to application site or blood vessel. The fulvestrant nanosphere/microsphere can be used to treat metastatic advanced breast cancer in post-menopausal woman.

Claims (26)

1. A method of preparing fulvestrant microsphere, wherein the fulvestrant microsphere comprises:

1) fulvestrant or pharmaceutically acceptable salt or solvate thereof and

2) a methoxy ended polyethylene glycol-polylactic acid block copolymer,

wherein the particle size of the fulvestrant microsphere is between 10 μm and 1 mm, the fulvestrant microsphere comprises between 16.5% and 50% weight of fulvestrant or pharmaceutically acceptable salt or solvate thereof based on the amount of fulvestrant; and

wherein the method is spray drying method.

2. The method of claim 1 , wherein the fulvestrant microsphere comprises between 20% and 30% weight of fulvestrant or pharmaceutically acceptable salt or solvate thereof based on the amount of fulvestrant.

3. The method of claim 1 , wherein the methoxy ended polyethylene glycol-polylactic acid block copolymer is composed of hydrophilic fragment polyethylene glycol and lipophilic fragment polylactic acid.

4. The method of claim 1 , wherein the particle size of the fulvestrant microsphere is 10˜500 μm.

5. The method according to claim 1 , wherein the spray drying method includes the steps of:

a. dissolving or dispersing the fulvestrant in the solvent system containing dissolved methoxy ended polyethylene glycol-polylactic acid block copolymer;

b. spraying into the drying tower of spray drying equipments in the form of spray, and drying, isolating, collecting.

6. The method of claim 3 , wherein the structural formula of the methoxy ended polyethylene glycol-polylactic acid block copolymer is

7. The method of claim 6 , wherein m=11˜227, n=70˜2083.

8. The method of claim 6 , wherein m=22˜113, n=139˜1111.

9. The method of claim 3 , wherein the value of hydrophile-lipophile balance (HLB) of the methoxy ended polyethylene glycol-polylactic acid block copolymer is between 0.01 and 19.84.

10. The method of claim 9 , wherein the HLB value is between 0.4 and 12.0.

11. The method of claim 9 , wherein the HLB value is between 1.47 and 15.0.

12. The method of claim 5 , wherein the solvent of the methoxy ended polyethylene glycol-polylactic acid block copolymer is one or more of dichloromethane, trichloromethane, methylhydrofuran, ethanol, and ethyl acetate.

13. The method of claim 5 , wherein the concentration of the methoxy ended polyethylene glycol-polylactic acid block copolymer in the solvent system is 0.1%˜50% (g/ml).

14. The method of claim 5 , wherein the concentration of the dissolved or dispersed fulvestrant in the solvent system containing solved methoxy ended polyethylene glycol-polylactic acid block copolymer is 0.01%˜50% (g/ml).

15. The method of claim 5 , wherein the inlet air temperature of the drying tower is 30° C.˜80° C.

16. The method of claim 5 , wherein the solvent system further comprises a plasticizer, an antisticking agent or both.

17. The method of claim 16 , wherein the plasticizer is one or more of dimethyl benzoate, diethyl benzoate, dibutyl benzoate, dibutyl sebacate, tributyl citrate, acetyl tributyl citrate, and glyceryl triacetate.

18. The method of claim 16 , wherein the mass percent of the plasticizer to the methoxy ended polyethylene glycol-polylactic acid block copolymer is 0%˜50%.

19. The method of claim 16 , wherein the antisticking agent is one or more of cholesterol, glycerol monostearate, talc powder, silica gel, and magnesium stearateand.

20. The method of claim 16 , wherein the mass percent of the antisticking agent to the methoxy ended polyethylene glycol-polylactic acid block copolymer is 0%˜100%.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 031664 FRAME 0797. ASSIGNOR(S) HEREBY CONFIRMS THE SHOULD READ XI'AN LIBANG PHARMACEUTICAL TECHNOLOGY CO., LTD.. Recorded Jan 6, 2014
From: HU, RENLE; WANG, JIUCHENG; JIAO, YAQI; LIANG, HUA; DING, DUOHAO
To: XI'AN LIBANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
Reel/Frame 031923/0160 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 031559 FRAME 0952. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE NAME SHOULD READ XI'AN LIBANG PHARMACEUTICIAL TECHNOLOGY CO., LTD. Recorded Nov 18, 2013
From: HU, RENLE; WANG, JIUCHENG; JIAO, YAQI; LIANG, HUA; DING, DUOHAO
To: XI'AN LIBANG PHARMACEUTICIAL TECHNOLOGY CO., LTD
Reel/Frame 031664/0797 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2013
From: HU, RENLE; WANG, JIUCHENG; JIAO, YAQI; LIANG, HUA; DING, DUOHAO
To: XI'AN LIBANG PHARAMCEUTICIAL TECHNOLOGY CO., LTD
Reel/Frame 031559/0952 →
Continuity (2)
Division 13255054
Related Publication 20140042654A1 · Feb 13, 2014